Examkin

Soru

Zorluk: ZorPharmacologic Interventions

During a routine oncology clinic visit, a 71-year-old male complains of progressive right calf pain and swelling over the past three days. He was diagnosed with advanced gastric adenocarcinoma three months ago and is currently receiving palliative chemotherapy. He has no history of recent trauma, surgery, or prolonged immobilization. His temperature is 37.1°C (98.8°F), blood pressure is 128/78 mmHg, pulse is 88/min, and respiratory rate is 14/min. Physical examination reveals an erythematous and edematous right lower leg that is tender to palpation. A lower extremity venous Doppler ultrasound confirms an acute deep venous thrombosis in the right popliteal and femoral veins. Laboratory studies show a hemoglobin of 10.2 g/dL, platelet count of 185,000/mm³, and creatinine of 1.0 mg/dL (estimated glomerular filtration rate: 72 mL/min). Which of the following is the most appropriate pharmacologic intervention for this patient's acute thrombosis?

  1. Subcutaneous enoxaparinCevap
  2. B
    Oral rivaroxaban
  3. C
    Oral warfarin
  4. D
    Intravenous unfractionated heparin
  5. E
    Oral aspirin

Cevap

Subcutaneous enoxaparin
Subcutaneous enoxaparin (a low-molecular-weight heparin) is the preferred initial and long-term anticoagulant for cancer-associated thrombosis in patients with luminal gastrointestinal or urothelial malignancies. While direct oral anticoagulants are considered an appropriate first-line choice for most cancer-associated VTEs, large randomized controlled trials have demonstrated a significantly higher risk of major mucosal bleeding when DOACs are used in patients with intact GI or GU mucosal tumors. Therefore, LMWH remains the standard of care in this high-risk subpopulation.

Adım Adım Çözüm

1
Identify the primary clinical diagnosis.
The patient has an acute deep venous thrombosis (DVT) in the setting of active gastric cancer (cancer-associated thrombosis).
Recent onset of unilateral leg swelling with ultrasound confirmation establishes the diagnosis of DVT.
2
Evaluate standard pharmacologic options for cancer-associated VTE.
Direct oral anticoagulants (DOACs) and low-molecular-weight heparins (LMWH) are the mainstays of therapy.
Both classes have proven efficacy in treating venous thromboembolism in the oncology population.
3
Assess for specific contraindications based on the patient's underlying malignancy.
The patient has a luminal gastrointestinal malignancy (gastric adenocarcinoma).
Clinical guidelines advise against DOACs in patients with active gastrointestinal or urothelial mucosal lesions due to a significantly elevated risk of major hemorrhage.
4
Select the safest effective intervention.
Subcutaneous enoxaparin is chosen over oral rivaroxaban.
LMWH provides effective anticoagulation while minimizing the high bleeding risk associated with DOACs in this specific cancer subtype.

Anahtar Kavram

Selection of low-molecular-weight heparin over direct oral anticoagulants in cancer-associated venous thromboembolism when the patient has an active luminal gastrointestinal or genitourinary malignancy.
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru